Epilepsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Epilepsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epilepsy - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Epilepsy (Central Nervous System) pipeline landscape.

Epilepsy is a neurological disorder characterized by the transmission of abnormal signals produced by a group of neurons in the brain which causes seizures. This leads to brief disruptions of the senses and short periods of unconsciousness or convulsions. Symptoms of epilepsy are repeated seizures, weakness, and anxiety, loss of consciousness and contraction, or jerking, of body muscles. Main causes of epilepsy include low oxygen during birth, head injuries that occur during birth or from accidents during youth or adulthood, brain tumors, genetic conditions that result in brain injury, such as tuberous sclerosis, infections such as meningitis or encephalitis, and stroke or any other type of damage to the brain.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Epilepsy - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Epilepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Epilepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Epilepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 14, 28, 27, 4, 141, 41 and 6 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 23 and 3 molecules, respectively.

Epilepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Epilepsy (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Epilepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Epilepsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Epilepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Epilepsy (Central Nervous System)

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Epilepsy (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Epilepsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned
Companies Mentioned

a:head Bio AG
Aadi Bioscience Inc
Accure Therapeutics SL
Advanced Neural Dynamics Inc
Advicenne SA
Aequus Pharmaceuticals Inc
AfaSci Inc
Affectis Pharmaceuticals AG
AgoneX Biopharmaceuticals Inc
Altamira Therapeutics Ltd
AMO Pharma Ltd
Anavex Life Sciences Corp
Aphios Corp
Apteeus SAS
Aquestive Therapeutics Inc
Arovella Therapeutics Ltd
Aucta Pharmaceuticals LLC
Aurum Biosciences Ltd
Avicanna Inc
Azurity Pharmaceuticals Inc
B&A Therapeutics
Baergic Bio Inc
BCWorld Pharm Co Ltd
Bio-Pharm Solutions Co Ltd
Bioasis Technologies Inc
Bioinnotis
Biom Therapeutics LLC
Biorchestra Co Ltd
Biovista Inc
Bloom Science Inc
Bright Minds Biosciences Inc
Bristol-Myers Squibb Co
CAMP4 Therapeutics Corp
Cann Pharmaceutical Australia Ltd
Cavion LLC
Celavie Biosciences LLC
Cellix Bio Pvt Ltd
Cerebral Therapeutics Inc
Cerecin Pte Ltd
Cerevel Therapeutics Holdings Inc
Coda Biotherapeutics Inc
Corestem Inc
Corlieve Therapeutics SAS
Crossject SA
CSL Ltd
Cure Pharmaceutical Holding Corp
CuroNZ Ltd
CURx Pharmaceuticals Inc
Cypralis Ltd
Eisai Co Ltd
Eliem Therapeutics Inc
Encoded Therapeutics Inc
Engrail Therapeutics Inc
Epalex Corp
EpyGenix Therapeutics Inc
Equilibre Biopharmaceuticals Corp
ES Therapeutics LLC
Eton Pharmaceuticals Inc
Ferring Pharmaceuticals Inc
GABA Therapeutics Inc
GAOMA Therapeutics
Gene Therapy Research Institution Co Ltd
GenEp Inc
Genochem SAS
Genus Lifesciences Inc
Guangzhou Cellprotek Pharmaceutical Co Ltd
H. Lundbeck AS
Harbin Pharmaceutical Group Co Ltd
Herophilus
ImmunoChem Therapeutics LLC
InteRNA Technologies BV
Ionis Pharmaceuticals Inc
Iproteos SL
iQure Pharma Inc
Jazz Pharmaceuticals Plc
JC Pharma Inc
Johnson & Johnson
Ketogen Inc
Klaria Pharma Holding AB
Knopp Biosciences LLC
LATITUDE Pharmaceuticals Inc
Lead Discovery Center GmbH
Lexaria Bioscience Corp
LifeSplice Pharma LLC
Lipocine Inc
Longboard Pharmaceuticals Inc
Luminus Biosciences Inc
Marinus Pharmaceuticals Inc
Medicure Inc
Mediphage Bioceuticals Inc
Medlab Clinical Ltd
Mercaptor Discoveries Inc
Metys Pharmaceuticals AG
MGC Pharmaceuticals Ltd
Mucodel Pharma LLC
MyMD Pharmaceuticals, Inc
MyX Therapeutics Inc
Nasus Pharma Ltd
Navega Therapeutics Inc
Navitor Pharmaceuticals Inc
Neonc Technologies Inc
NeuCyte Inc
NeuExcell Therapeutics Inc
NeurAegis Inc
Neuraxpharm France SAS
Neurelis Inc
NeuroAdjuvants Inc
Neurocrine Biosciences Inc
Neuroene Therapeutics LLC
Neurona Therapeutics Inc
New Amsterdam Sciences Inc
Nissan Chemical Corp
Noema Pharma AG
NoNO Inc
NuBioPharma LLC
OB Pharmaceuticals
OMass Therapeutics Limited
Oncocross Co Ltd
Otsuka Pharmaceutical Co Ltd
Ovid Therapeutics Inc
OWP Pharmaceuticals Inc
Panaxia Pharmaceutical Industries Ltd
Pfizer Inc
PharmaTher Holdings Ltd
PharmatrophiX Inc
PIQUR Therapeutics AG
Praxis Precision Medicines Inc
Primetime Life Sciences LLC
Promius Pharma LLC
Proniras Corp
Protheragen Inc
Proveca Ltd
PTC Therapeutics Inc
Puretech Health Plc
Q-State Biosciences Inc
Reata Pharmaceuticals Inc
reMYND NV
RespireRx Pharmaceuticals Inc
RogCon Inc
Sage Therapeutics Inc
Saniona AB
Scientus Pharma Inc
SciSparc Ltd
Serina Therapeutics Inc
Shackelford Pharma Inc
Shanghai Lvdao Pharmaceutical Technology Co Ltd
Shanghai Zhimeng Biopharma Inc
Simcere Pharmaceutical Group Ltd
SK Biopharmaceuticals Co Ltd
SK Chemicals Co Ltd
Skye Bioscience Inc
SoVarGen Co Ltd
Spark Therapeutics Inc
Stoke Therapeutics Inc
StrideBio Inc
Sumitomo Dainippon Pharma Co Ltd
Sun Pharma Advanced Research Company Ltd
Supernus Pharmaceuticals Inc
Sustained Nano Systems LLC
Taho Pharmaceuticals Ltd
Takeda Pharmaceutical Co Ltd
Tavanta Therapeutics Inc
Taysha Gene Therapies Inc
Techfields Pharma Co Ltd
Tevard Biosciences LLC
The Cell Factory BVBA
Trevena Inc
UCB SA
Ultragenyx Pharmaceutical Inc
Viatris Inc
Virpax Pharmaceuticals Inc
VistaGen Therapeutics Inc
Vitality Biopharma Inc
Vyripharm Biopharmaceuticals
Whan In Pharm Co Ltd
Xenon Pharmaceuticals Inc
Xeris Biopharma Holdings Inc
XPhyto Therapeutics Corp
XWPharma Ltd
Zhejiang Conba Pharmaceutical Co Ltd
Zogenix Inc
Zynerba Pharmaceuticals Inc